Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “GLYCINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources

Glycine-evoked currents in acutely dissociated neurons of the guinea pig ventral cochlear nucleus.

1. Glycine was applied to acutely dissociated neurons of the guinea pig ventral cochlear nucleus (VCN) with the use of iontophoresis. With approximately equal chloride concentrations in the extra- and intracellular solutions (i.e., chloride equilibrium potential = 0 mV), cells held at -60 mV responded with inward currents that were 1-10 nA in amplitude, had rise times of approximately 50 ms, and decayed to half of the peak amplitude in 50-600 ms. More than 95% of cells with diameters > 12 microns responded to glycine. Response amplitude and area increased with increasing duration of the iontophoretic pulse. Response amplitude saturated at pulse durations of 60-80 ms, whereas response area did not exhibit saturation for pulse durations of 10-100 ms. 2. The glycine antagonist strychnine was added to the extracellular solution at concentrations of 0.5-500 nM to evaluate its effect on glycine-evoked responses. Strychnine produced a 50% reduction in the response at a concentration of 12 nM and the dose-response function had a limiting slope (Hill coefficient) of 1.4. 3. Changes in glycine-evoked currents as a function of cell membrane potential were examined in the presence of tetrodotoxin, tetraethylammonium chloride, and 4-aminopyridine, which block sodium and potassium conductances activated by depolarization. Both the amplitude and the decay of glycine-evoked currents displayed a voltage dependence. Under conditions where the glycine currents reversed at -35 mV, the amplitudes of responses evoked at membrane potentials of 0 mV were 2.3 times larger than those of responses evoked at -70 mV. The decay time constant at 0 mV was 1.49 times longer than that at -70 mV. 4. Acutely dissociated neurons of the VCN previously have been classified on the basis of the absence (type I) or presence (type II) of a low-threshold outward current. Type I cells fire repetitively in response to current pulses, whereas type II cells fire transiently. Glycine-evoked responses were compared in cells identified electrophysiologically as type I or type II on the basis of previously established criteria under voltage clamp. The average amplitudes of responses recorded at a membrane potential of -70 mV were 1.1 and 1.3 nA for type I and type II cells, respectively. The rise time of the glycine current for the two groups of cells was similar (52 ms for type I and 57 ms for type II), but the decay of currents to half-maximum amplitude following the offset of the iontophoretic pulse was longer in type II cells (340 ms) than in type I cells (173 ms). No differences between the two groups were noted with regard to the outward rectification of peak currents or the voltage dependence of current decay. 5. The reversal potential of glycine-evoked responses was determined in extracellular solutions with varying chloride concentrations. The change in the glycine reversal potential (54 mV) for a 10-fold change in chloride concentration was similar to the change in the chloride equilibrium potential (58 mV) over the same range of extracellular chloride concentrations. A similar result was obtained by maintaining the extracellular chloride concentration constant and varying the chloride concentration in the intracellular solution. Glycine-evoked responses were not affected by changes in the potassium or sodium equilibrium potentials. The glycine receptors are therefore principally permeable to chloride. 6. In the VCN, glycine-mediated currents are readily evoked from the majority of larger neurons, indicating an abundance of glycine receptors on the somata and proximal processes of these neurons. The properties of glycine receptors in VCN and other areas of the nervous system are generally similar. The voltage dependence of glycine-evoked currents implies that the inhibitory effectiveness of glycine receptors in VCN increases nonlinearly with depolarization.

Animals↗

Transport is the primary determinant of glycine content in retinal neurons.

This study demonstrates that in mammalian and nonmammalian species it is possible to deplete selectively and reversibly retinal glycinergic neurons of their content of glycine by exposure to sarcosine, a competitive inhibitor of glycine transporter 1 (glyt-1). This observation was used as a tool to test the hypothesis that uptake of glycine rather than de novo synthesis is the main determinant of glycine content in retinal neurons. Isolated retinae were depleted of immunocytochemically detectable pools of glycine. Thereafter retinae were exposed either to physiological medium containing glycine or to medium lacking glycine but containing precursors for the synthesis of glycine. Retinae exposed to glycine-containing medium rapidly recovered their content of glycine, whereas retinae exposed to medium lacking glycine but containing serine, a substrate for synthesis of glycine, showed only a slow recovery of immunoreactivity for glycine in a few amacrine cells. These data indicate that uptake of glycine is the primary determinant of glycine content in most retinal glycinergic neurons. The origins of the extracellular pools of glycine remain to be identified; however, it is suggested that such glycine may be derived from the vitreous humor and that in turn this glycine may be derived from the peripheral circulation.

Animals↗

Glycine modulates ethanol inhibition of heteromeric N-methyl-D-aspartate receptors expressed in Xenopus oocytes.

Ethanol inhibits N-methyl-D-aspartate (NMDA) receptor-mediated responses at pharmacologically relevant concentrations, suggesting that inhibition of NMDA receptors may underlie some of the actions of ethanol in the central nervous system. We examined the ability of glycine to modulate ethanol inhibition of four recombinant heteromeric NMDA receptors (NR1a/NR2A through NR2D) expressed in Xenopus oocytes. Ethanol dose-response analysis revealed enhanced inhibitory efficacy of ethanol in the presence of subsaturating glycine concentrations at the NR1/NR2A, NR1/NR2C, and NR1/NR2D receptors. When assayed over a range of glycine concentrations, ethanol exhibited both glycine-reversible and glycine-independent inhibition of NMDA receptors. In contrast, ethanol inhibition of recombinant NMDA receptors was independent of NMDA concentration. Glycine reversal of ethanol inhibition suggested that ethanol might lower the affinity of glycine for the NMDA receptor and thereby decrease response magnitude. Consistent with this hypothesis, ethanol significantly reduced glycine affinity at NR1/NR2A and NR1/NR2C receptors. Evaluation of the glycine-independent component of ethanol inhibition demonstrated that in the presence of saturating concentrations of glycine, the NR1/NR2A and NR1/NR2B receptors were more sensitive to ethanol than the NR1/NR2C and NR1/NR2D receptors. Activation of the NR1/NR2D heteromers by NMDA and low concentrations of glycine elicited responses characterized by an initial peak followed by a lower-amplitude plateau response, which is consistent with glycine-sensitive desensitization as previously described for native NMDA receptors. In addition, nondesensitizing NR1/NR2B responses elicited in the presence of subsaturating concentrations of glycine were frequently converted into desensitizing responses by the addition of ethanol, an effect that was reversed with increasing glycine concentrations. The ability of ethanol to promote glycine-sensitive desensitization further suggests an interaction between glycine and ethanol inhibition of the NMDA receptor. Taken together, the results of the present report demonstrate that ethanol inhibition of NMDA receptors has both glycine-reversible and glycine-independent components, suggesting two distinct molecular mechanisms for ethanol inhibition of NMDA receptors.

Animals↗

Characterization and regional distribution of strychnine-insensitive [3H]glycine binding sites in rat brain by quantitative receptor autoradiography.

Recent evidence suggests that a strychnine-insensitive glycine modulatory site is associated with the N-methyl-D-aspartate receptor-channel complex. A quantitative autoradiographic method was used to characterize the pharmacological specificity and anatomical distribution of strychnine-insensitive [3H]glycine binding sites in rat brain. [3H]Glycine binding was specific, saturable, reversible, pH and temperature-sensitive and of high affinity. [3H]Glycine interacted with a single population of sites having a KD of approximately 200 nM and a maximum density of 6.2 pmol/mg protein (stratum radiatum, CA1). Binding exhibited a pharmacological profile similar to the physiologically defined strychnine-insensitive glycine modulatory site. Binding was stereoselective; the rank order of potency of simple amino acids as displacers of binding was: glycine greater than D-serine greater than D-alanine greater than L-serine greater than L-alanine greater than L-valine greater than D-valine. Binding was not altered by the inhibitory glycine receptor ligand, strychnine, by the glutamate agonists, quisqualate and kainate, or by GABA receptor selective ligands. Most competitive agonists or antagonists of the N-methyl-D-aspartate recognition site were ineffective displacers of glycine binding. The exceptions were the aminophosphono series of antagonists, D-alpha-aminoadipate, gamma-D-glutamyglycine and beta-D-aspartylaminomethylphosphonic acid. However, the inhibition of [3H]glycine binding produced by the aminophosphono compounds could be accounted for by the level of glycine contamination present in these compounds. The non-competitive NMDA receptor-channel blockers, phencyclidine, its thienyl derivative, and MK-801 did not alter glycine binding. Kynurenate, glycine methylester, L-serine-O-sulfate, L-homocysteic acid, and several glycine-containing dipeptides were effective displacers of glycine binding. Structure-activity relations of agonists and antagonists of the strychinine-insensitive glycine binding site are discussed. The distribution of strychnine-insensitive [3H]glycine binding was heterogeneous with the following rank order of binding densities: hippocampus greater than cerebral cortex greater than caudate-putamen greater than or equal to thalamus greater than cerebellum greater than brain stem. This distribution of binding was correlated with N-methyl-D-aspartate-sensitive [3H]glutamate binding (r2 = 0.77; P less than 0.001; Pearson product-moment) and [3H]thienylcyclohexylpiperidine binding (r2 = 0.72; P less than 0.001). These observations are consistent with the hypothesis that the strychnine-insensitive glycine binding site is closely associated with the N-methyl-D-aspartate receptor-channel complex.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗

Glycine regulation of the N-methyl-D-aspartate receptor-gated ion channel in hippocampal membranes.

The N-methyl-D-aspartate receptor-gated ion channel (NMDA channel) is regulated by glycine. To examine the interaction of glycine and NMDA receptor ligands on NMDA channel function, we used a biochemical marker of channel opening, [3H]N-(1-[thienyl]cyclohexyl)piperidine (TCP). We quantified [3H]glycine,L-[3H]glutamate, and TCP binding in an identical membrane preparation. This allowed direct comparison of NMDA and glycine receptor occupancy and channel activation. Glycine increased the association and dissociation rates of NMDA-dependent TCP binding to hippocampal membranes, without altering the Kd or Bmax for TCP binding. Structurally similar amino acids mimicked the action of glycine, with D-isomers being more potent than L-isomers. The potency of glycine in regulating TCP binding matched that for displacing [3H]glycine. Glycine stimulation of TCP binding required the presence of NMDA agonists and was inhibited by the NMDA antagonist D-2-amino-5-phosphonovaleric acid. Glycine stimulation of NMDA-dependent TCP binding was not associated with an increase in agonist binding to the NMDA receptor. Likewise, NMDA stimulation of glycine-dependent TCP binding was not associated with an increase in the binding of glycine to the glycine receptor. These findings permit the following conclusions: 1) glycine stimulates TCP binding solely by increasing the access of TCP to its site in the NMDA channel; 2) TCP binding can be used to quantify glycine regulation of the NMDA channel; 3) a stereospecific glycine receptor, as part of the NMDA receptor-channel complex, regulates NMDA-evoked channel opening by a mechanism not involving increased agonist binding to the NMDA receptor. Thus, it appears that the mechanism of glycine and NMDA receptor regulation of the NMDA channel is analogous to that of a two-key lock; both receptors, by independent and mutually required mechanisms, alter channel conformation to allow ion passage.

Allosteric Regulation↗

Genetic variants in ALDH1L1 and GLDC influence the serine-to-glycine ratio in Hispanic children.

BACKGROUND: Glycine is a proteogenic amino acid that is required for numerous metabolic pathways, including purine, creatine, heme, and glutathione biosynthesis. Glycine formation from serine, catalyzed by serine hydroxy methyltransferase, is the major source of this amino acid in humans. Our previous studies in a mouse model have shown a crucial role for the 10-formyltetrahydrofolate dehydrogenase enzyme in serine-to-glycine conversion. OBJECTIVES: We sought to determine the genomic influence on the serine-glycine ratio in 803 Hispanic children from 319 families of the Viva La Familia cohort. METHODS: We performed a genome-wide association analysis for plasma serine, glycine, and the serine-glycine ratio in Sequential Oligogenic Linkage Analysis Routines while accounting for relationships among family members. RESULTS: All 3 parameters were significantly heritable (h2&#xa0;=&#xa0;0.22-0.78; P&#xa0;<&#xa0;0.004). The strongest associations for the serine-glycine ratio were with single nucleotide polymorphisms (SNPs) in aldehyde dehydrogenase 1 family member L1 (ALDH1L1) and glycine decarboxylase (GLDC) and for glycine with GLDC (P&#xa0;<&#xa0;3.5&#xa0;&#xd7;&#xa0;10-8; effect sizes, 0.03-0.07). No significant associations were found for serine. We also conducted a targeted genetic analysis with ALDH1L1 exonic SNPs and found significant associations between the serine-glycine ratio and rs2886059 (&#x3b2; = 0.68; SE, 0.25; P&#xa0;=&#xa0;0.006) and rs3796191 (&#x3b2; = 0.25; SE, 0.08; P&#xa0;=&#xa0;0.003) and between glycine and rs3796191 (&#x3b2; = -0.08; SE, 0.02; P&#xa0;=&#xa0;0.0004). These exonic SNPs were further associated with metabolic disease risk factors, mainly adiposity measures (P&#xa0;<&#xa0;0.006). Significant genetic and phenotypic correlations were found for glycine and the serine-glycine ratio with metabolic disease risk factors, including adiposity, insulin sensitivity, and inflammation-related phenotypes [estimate of genetic correlation = -0.37 to 0.35 (P&#xa0;<&#xa0;0.03); estimate of phenotypic correlation = -0.19 to 0.13 (P&#xa0;<&#xa0;0.006)]. The significant genetic correlations indicate shared genetic effects among glycine, the serine-glycine ratio, and adiposity and insulin sensitivity phenotypes. CONCLUSIONS: Our study suggests that ALDH1L1 and GLDC SNPs influence the serine-to-glycine ratio and metabolic disease risk.

Child↗

Cellular expression of glycine transporter 2 messenger RNA exclusively in rat hindbrain and spinal cord.

High-affinity transporters mediate the removal of released neurotransmitters from synapses, thereby terminating their synaptic action. A novel glycine transporter has recently been cloned from a rat brain complementary DNA library. In this study we examined, by means of in situ hybridization with 35S-labelled oligodeoxynucleotide probes, the distribution of messenger RNAs encoding glycine transporter 2 in the rat CNS. Moreover, adjacent series of sections were labelled with [3H]strychnine to reveal the regional distribution of strychnine-sensitive glycine receptors. A very discrete pattern of distribution of the transcripts was found exclusively at the level of the brainstem/cerebellum and spinal cord. In the cerebellum, Golgi cells in the granule cell layer as well as a subpopulation of neurons in the interposed nuclei were consistently labelled. In the brainstem, where the bulk of the labelling was concentrated, several nuclei showed a high level of transcript expression, including the superior olivary complex, nucleus of the trapezoid body and the ventral nucleus of the lateral lemniscus. In the spinal cord, many neurons throughout all layers were labelled, including putative Renshaw cells and a few large neurons at the border of layers 7 and 9. No labelled cells were detected at the levels of the fore- and midbrain. The distribution of glycine transporter 2 messenger RNA-containing cell bodies was very different to that of other glycine transporter messenger RNAs (glycine transporter 1a and glycine transporter 1b), but similar to that of known glycine-immunoreactive neurons and correlated very well with that of strychnine-sensitive glycine receptors in most CNS regions except cerebellum. Our results show that glycine transporter 2 (but not glycine transporter 1) in the brainstem, spinal cord and cerebellum is probably involved in the reuptake of glycine from synapses containing classical strychnine-sensitive glycine receptors. Our findings also suggest that glycine acts as a neurotransmitter in cerebellar Golgi neurons. Whether the synaptic concentration of glycine, as co-agonist at NMDA receptors, is regulated (if at all) by transaminase activity or by a glycine transporter (GLYT1a?) distinct from that described here is not yet known.

Amino Acid Transport Systems, Neutral↗

Size-related colocalization of glycine and glutamate immunoreactivity in frog and rat vestibular afferents.

Presence and distribution of glutamate, glycine, GABA and beta-alanine in VIIIth nerves of frogs and rats were investigated with postembedding immunocytochemical methods on serial semithin sections. In Scarpa's ganglion of the frog, all cell bodies were glutamate immunoreactive. About 17% of the cells per section were also glycine immunoreactive, but none were GABA or beta-alanine immunoreactive. The mean diameter of glycine-positive cell bodies (26.7 +/- 6.9 microns; N = 130) was significantly (P < 0.0001) larger than that of glycine-negative cell bodies (15.7 +/- 5.4 microns; N = 272). The intensity of glutamate immunostaining decreased with cell diameter, whereas the intensity of glycine immunostaining increased with cell diameter. As a result, the staining intensities for glutamate and glycine in a given cell were negatively correlated. Glycine immunoreactivity was also present in a size-related manner in distal and proximal afferent fibers. The majority of thin fibers (< 4 microns) was glycine negative, whereas most of the thick fibers (> 10 microns) were glycine positive. Glycine-positive fibers were observed in the sensory epithelial of all end organs in the inner ear. The saccular macula and its nerve, however, contained only few glycine immunoreactive structures. In Scarpa's ganglion of the rat, all cells were immunoreactive for glutamate, about 12% for colocalized glycine, and none for GABA or beta-alanine. Glycine-positive cell bodies were significantly (P < 0.0001) larger (32.2 +/- 5.2 microns; N = 82) than glycine-negative cell bodies (25.1 +/- 5.3 microns; N = 274). Cell bodies in the spiral ganglion were only glutamate immunoreactive, whereas staining for glutamate, glycine, and GABA was dense in the ventral cochlear nucleus. These results demonstrate that thicker vestibular afferent fibers represent a particular subpopulation that differs from the majority of thinner afferents due to their glycine immunoreactivity.

Alanine↗

The biochemical basis for the conjugation of bile acids with either glycine or taurine.

All animals, except for the placental mammals, conjugate their bile acids exclusively with taurine. However, in certain of the placental mammals, glycine conjugates are also found. The basis for the appearance of glycine conjugation among the placental mammals was investigated. The reaction of choloyl-CoA with glycine and taurine, as catalysed by the soluble fraction from guinea-pig liver, had a high affinity for taurine and a poor affinity for glycine. The predominant synthesis of glycine conjugates in the guinea pig can be related to the fact that guinea-pig liver contains an unusually low concentration of taurine and a high concentration of glycine. Rabbits make exclusively glycine conjugates and their livers also contain low concentrations of taurine. However, the biochemical basis for their glycine conjugation is more straightforward than in the guinea pig in that the soluble fraction from rabbit liver has a high affinity for glycine and a poor affinity for taurine. Alternative-substrate-inhibition studies with glycine and taurine in soluble fractions from guinea-pig and rabbit liver revealed that glycine and taurine were mutually inhibitory. This suggests that there is only one enzyme for glycine and taurine conjugation in these tissues. The soluble fractions from bovine liver and human liver also made both glycine and taurine conjugates and evidence is presented that suggests that there is only one enzyme in these tissues too. Even the rat, which excretes mostly taurine conjugates, could make both glycine and taurine conjugates in vitro. However, in contrast with all of the placental mammals studied, the supernatant fraction from liver of the chicken, and other non-mammals, could not make glycine conjugates even in the presence of very high concentrations of glycine.

Acyltransferases↗

Dietary glycine prevents the development of liver tumors caused by the peroxisome proliferator WY-14,643.

Previous studies demonstrated that dietary glycine prevents elevated rates of cell proliferation following treatment with the peroxisome proliferator and liver carcinogen WY-14,643. Since increased cell replication is associated with the development of hepatic cancer caused by peroxisome proliferators, glycine may have anti-cancer properties. Therefore, experiments were designed to test the hypothesis that dietary glycine would inhibit the hepatocarcinogenic effect of WY-14,643. Male F344 rats were fed four different NIH 07-based diets: 5% glycine; 5% valine for nitrogen balance (control); 0.1% WY-14,643 + 5% valine (WY-14,643); 0.1% WY-14,643 + 5% glycine (WY-14,643 + glycine). Food consumption did not differ among the groups, but WY-14,643-fed rats weighed 10-25% less than expected based on previous studies. Serum glycine levels were elevated 4-5-fold by glycine-containing diets; however, the 10-fold increase in peroxisomal enzyme activity caused by WY-14,643 was unaffected by the addition of 5% glycine to the diet. After 22 weeks, livers from rats fed WY-14,643 had a similar incidence and multiplicity of proliferative lesions (foci and adenomas) to those fed WY-14,643 + glycine. Moreover, cell proliferation in the surrounding 'normal' parenchyma (labeling index approximately 4%) and foci (labeling index approximately 50%) did not differ between WY-14,643 and WY-14,643 + glycine-fed rats. However, after 51 weeks of dietary exposure to WY-14,643, glycine prevented formation of small (0-5 mm diameter) tumors by 23% and inhibited the development of medium size (5-10 mm) tumors by 64%. Furthermore, glycine prevented the formation of the largest tumors (>10 mm) by nearly 80%. Thus, glycine did not inhibit early foci formation; however, it significantly decreased their ability to progress to tumors. Moreover, the inhibitory effect of glycine was greater with increasing tumor size. These studies demonstrate that dietary glycine prevents the development of hepatic tumors caused by the peroxisome proliferator WY-14,643 consistent with the idea that it may be an effective chemopreventive agent.

Animals↗

Effect of glycine in dog and rat liver transplantation.

Glycine has been shown to protect renal tubule cells and hepatocytes from ischemia, ATP depletion, and cold storage injury. Glycine may be a useful additive to organ preservation solutions or suppress reperfusion injury by infusion into recipients of liver transplantation. In this study, the effects of glycine on survival and postoperative liver injury were studied in the rat and dog orthotopic transplant model. Rat livers preserved for 30 hr in the University of Wisconsin (UW) solution were 50% viable (3 of 6 survivors for 7 days). When glutathione was replaced by 10 mM glycine, survival increased to 100% (6 of 6). There was a significant reduction in hepatocellular injury at the end of preservation (lactate dehydrogenase [LDH] in the pretransplant flush-out of the liver was lower in the glycine group) and after transplantation (serum LDH concentration 6 hr after transplant was lower in the glycine group). In the dog, omission of glutathione from the UW solution resulted in 33% survival (48-hr preservation model) versus 100% survival with glutathione. Replacing glutathione in the UW solution by glycine did not improve survival (33% after 48 hr of preservation). However, when glycine was given to recipients of livers preserved in the UW solution for 24 or 48 hr, there was a decrease in the degree of hepatocellular injury. After 48 hr of preservation, peak aspartate aminotransferase, alanine aminotransferase, and LDH were reduced by about 45-55% when glycine was given to the recipient. Although the differences, with and without glycine treatment of the recipients, did not reach statistical significance, there was a noticeable reduction in hepatocellular injury with glycine. There was 100% survival of dogs in the groups that received livers preserved with the UW solution plus or minus glycine infusion. Hepatamine, a parenteral nutrition solution containing glycine and other amino acids increased hepatocellular injury (higher concentrations of aspartate aminotransferase, alanine transferase, and LDH versus control 48-hr preserved livers), although all dogs survived. This study shows that glycine is cytoprotective when administered to recipients of livers preserved for 24 or 48 hr and suppresses hepatocellular injury, as reflected in a reduction in the concentration of serum enzymes. However, the differences, with and without glycine, were, at best, marginal and further studies are needed to determine whether glycine would make a significant improvement in liver preservation and prevent primary nonfunction.

Adenosine↗

Regulation of the glycine cleavage system in the isolated perfused rat liver.

The catabolism of glycine in the isolated perfused rat liver was investigated by measuring the production of 14CO2 from [1-14C]- and [2-14C]glycine. Production of 14CO2 from [1-14C]glycine was maximal as the perfusate glycine concentration approached 10 mM and exhibited a maximal activity of 125 nmol of 14CO2 X g-1 X min-1 and an apparent Km of approximately 2 mM. Production of 14CO2 from [2-14C]glycine was much lower, approaching a maximal activity of approximately 40 nmol of 14CO2 X g-1 X min-1 at a perfusate glycine concentration of 10 mM, with an apparent Km of approximately 2.5 mM. Washout kinetic experiments with [1-14C]glycine exhibited a single half-time of 14CO2 disappearance, indicating one metabolic pool from which the observed 14CO2 production is derived. These results indicate that the glycine cleavage system is the predominant catabolic fate of glycine in the perfused rat liver and that production of 14CO2 from [1-14C]glycine is an effective monitor of metabolic flux through this system. Metabolic flux through the glycine cleavage system in the perfused rat liver was inhibited by processes which lead to reduction of the mitochondrial NAD(H) redox couple. Infusion of beta-hydroxybutyrate or octanoate inhibited 14CO2 production from [1-14C]glycine by 33 and 50%, respectively. Alternatively, infusion of acetoacetate stimulated glycine decarboxylation slightly and completely reversed the inhibition of 14CO2 production by octanoate. Metabolic conditions which are known to cause a large consumption of mitochondrial NADPH (e.g. ureogenesis from ammonia) stimulated glycine decarboxylation by the perfused rat liver. Infusion of pyruvate and ammonium chloride stimulated production of 14CO2 from [1-14C]glycine more than 2-fold. Lactate plus ammonium chloride was equally as effective in stimulating glycine decarboxylation by the perfused rat liver, while alanine plus ammonium chloride was ineffective in stimulating 14CO2 production.

Acetoacetates↗

Immunocytochemical localization of glycine in the lamprey spinal cord with reference to GABAergic and glutamatergic synapses: a light and electron microscopic study.

The distribution of glycine immunoreactivity in the lamprey (Lampetra fluviatilis and Ichthyomyzon unicuspis) spinal cord was studied at the light and electron microscopic levels by use of postembedding techniques and antibodies against glutaraldehyde-conjugated glycine. To determine if glycine may be co-stored with other amino acid transmitters, the levels of glycine immunolabeling in identified GABAergic and glutamatergic synapses were examined. The most intense glycine labeling occurred in axon profiles of different diameter distributed throughout the ventral and lateral columns, with the highest density in the areas bordering the lateral cell column. Intermediate levels of glycine labeling were present in certain interneurons in the lateral cell column and in stretch receptors (edge cells) at the lateral margin of the spinal cord. Most other cell bodies, including glutamatergic dorsal cells, were virtually unlabeled. Examination of adjacent sections incubated with GABA antiserum revealed that many of the glycine-containing cells and fibers also contained high levels of GABA. At the ultrastructural level, the glycine immunolabeling was accumulated in two morphologically distinct types of terminal, one of which co-contained GABA. The terminals which exhibited glycine, but not GABA immunoreactivity, contained flattened synaptic vesicles and formed symmetrical synaptic specializations. The terminals that exhibited both GABA and glycine labeling contained pleomorphic synaptic vesicles and had either symmetrical or asymmetrical synaptic specializations. In both cases the glycine labeling was accumulated over the synaptic vesicles. Examination of identified glutamatergic axons in glycine-labeled sections did not provide any evidence for an accumulation of glycine in the synaptic vesicles or other structures of these exons. The present study provide the first morphological description of the localization of glycine in the lamprey spinal cord. The results confirm previous physiological and pharmacological studies, which have implicated glycine as a major fast inhibitory transmitter in the interneuronal network for locomotion, and in a proportion of stretch receptor neurons. The data also show that a significant proportion of the GABAergic synapses, but not the glutamatergic synapses, may utilize glycine as co-transmitter.

Animals↗

Bergmann glial GlyT1 mediates glycine uptake and release in mouse cerebellar slices.

Glycine is an inhibitory neurotransmitter and is critical for NMDA receptor activation. These roles are dependent on extracellular glycine levels, which are regulated by Na(+)/Cl(-)-dependent glycine transporters (GlyTs) in neurones and glia. The glial GlyT subtype GlyT1 is well located to activate NMDA receptors. However, glial GlyTs have not been studied in an intact system thus far. Whole-cell patch-clamp recordings were obtained from Bergmann glia in mice cerebellar slices to determine whether these glia express functional GlyT1 that can mediate both glycine uptake and efflux. In the presence of a glycine receptor blocker, glycine and a substrate agonist for GlyT1, sarcosine, induced voltage-dependent inward currents that were abolished by removing external Na(+), identifying them as transport currents. Inhibitors of glycine transport through GlyT1 (sarcosine and (N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS)) reduced glycine currents by approximately 85%, consistent with positive immunostaining for GlyT1 in Bergmann glia while inhibitors of glycine transport through GlyT2 (4-benzyloxy-3,5-dimethoxy-N-[1-(dimethylaminocyclopently)methyl]benzamide (ORG 25543) and amoxapine) or through systems A and ASC did not affect glycine transport currents. Following internal glycine perfusion during the recording, outward currents progressively developed at -50 mV and external glycine-induced uptake currents were reduced. Using paired recordings of a Bergmann glial cell and a granule cell in the whole cell and outside-out modes, respectively, depolarizations of Bergmann glia to +20 mV induced a 73% increase in the open probability of glycine receptor channels in membrane patches of granule cells. This increase was prevented when NFPS was included in the bath solution. Overall, these results demonstrate for the first time that Bergmann glia express functional GlyT1 that can work in reverse at near-physiological ionic and internal glycine conditions in brain slices. These glial GlyTs can probably mediate glycine efflux under conditions of metabolic impairments like ischaemia.

Amino Acid Transport Systems, Neutral↗

Benzoate treatment and the glycine index in nonketotic hyperglycinaemia.

High-dose benzoate treatment aimed at reducing plasma glycine levels to normal reduces seizures and increases wakefulness in patients with nonketotic hyperglycinaemia (NKH). Since benzoate metabolism is dependent on the available glycine pool, and since the glycine pool is variably affected by the deficiency in the glycine cleavage enzyme system, we examined the importance of interpatient variability in benzoate requirement. To correct for the dietary glycine contribution, the glycine index was introduced as the molar requirement of benzoate dose necessary to normalize plasma glycine levels and subtracting from that the dietary glycine intake, both corrected for weight. The glycine index varied between 3.62 and 4.87 mmol/kg per day in five patients with a poor neurodevelopmental outcome and between 0.92 and 1.90 mmol/kg per day in four patients with a better neurodevelopmental outcome, and was 2.54 mmol/kg per day in a single patient with an intermediate outcome. The glycine index was stable over time within each patient. Exceeding the balance by either increasing food glycine intake or decreasing the benzoate dose resulted in increased glycine levels. Exceeding the glycine tolerance by increasing benzoate resulted in elevated and toxic levels of benzoate. The glycine index is a stable, individually specific parameter in patients with NKH. It has clinical consequences for the dose of benzoate required and the role of dietary management. Through its correlation with neurodevelopmental outcome, the glycine index points to potential genetic factors that could contribute to the psychomotor retardation in NKH.

Adolescent↗

Glycine binding to rat cortex and spinal cord: binding characteristics and pharmacology reveal distinct populations of sites.

Glycine is the principal inhibitory neurotransmitter in posterior regions of the brain. In addition, glycine serves as an allosteric regulator of excitatory neurotransmission mediated by the N-methyl-D-aspartate (NMDA) acidic amino acid receptor subtype. The studies presented here characterize [3H]glycine binding to washed membranes prepared from rat spinal cord and cortex, areas enriched in glycine inhibitory and NMDA receptors, respectively, in an attempt to define the glycine recognition sites on the two classes of receptors. Specific binding for [3H]glycine was seen in both cortex and spinal cord. Saturation analyses in cortex were best fitted by a two-site model with respective equilibrium dissociation constants (KD values) of 0.24 and 5.6 microM and respective maximal binding constants (Bmax values) of 3.4 and 26.7 pmol/mg of protein. Similar analyses in spinal cord were best fitted by a one-site model with a KD of 5.8 microM and Bmax of 20.2 pmol/mg of protein. Na+ had no effect on [3H]glycine binding to cortical membranes but increased the binding to spinal cord membranes by greater than 15-fold. This Na+-dependent binding may reflect glycine binding to the recognition site of the high-affinity, Na+-dependent glycine uptake system. Several short-chain, neutral amino acids displaced [3H]glycine binding from both cortical and spinal cord membranes. The most potent displacers of [3H]glycine binding to cortical membranes were D-serine and D-alanine, followed by the L-isomers of serine and alanine and beta-alanine. In contrast, D-serine and D-alanine were similar in potency to L-serine in spinal cord membranes. Compounds active at receptors for the acidic amino acids had disparate effects on the binding of [3H]glycine. At 10 microM, NMDA resulted in a 25% increase, whereas D- and L-2-amino-5-phosphonovaleric acid at 100 microM resulted in a 30% decrease, in [3H]glycine binding to cortical membranes. Kynurenic acid was the most potent of the acidic amino acid-related compounds at displacing [3H]glycine binding. In cortical membranes, kynurenic acid displacement was resolved into a high- and a low-affinity component; the high-affinity component displaced the high-affinity component of [3H]glycine binding.(ABSTRACT TRUNCATED AT 400 WORDS)

Amino Acids↗

Fall in blood pressure produced from discrete regions of the ventral surface of the medulla by glycine and lesions.

1. In cats anaesthetized with pentobarbitone sodium, atropinized by i.v. atropine methyl nitrate and artificially ventilated, experiments were carried out (a) to localize the site where glycine acts on the ventral surface of the medulla when, on topical application through paired Perspex rings caudal to the trapezoid bodies, it produces a fall in arterial blood pressure, (b) to compare the effects of uni- and bilateral application, and (c) to study the blood pressure effects produced by electrolytic lesions of the glycine-sensitive areas.2. Blood pressure fell only a little on unilateral application of glycine through one of the Perspex rings, but a pronounced fall occurred on its bilateral application. The fall was too large to be explained by two minimal responses added together. Thus the application of glycine to one side potentiated the depressor effect of glycine applied to the other side.3. By moving the paired Perspex rings rostrally or caudally to different positions on the medulla and determining for each position the effectiveness of glycine, the glycine-sensitive areas were found to be restricted to a 1.5 mm wide strip situated 1-2.5 mm caudal to the trapezoid bodies. By making electrolytic lesions within the limits of this strip the glycine-sensitive areas were found to be not wider than 1.5 mm in the mediolateral direction and to be situated about 4 mm lateral to the mid line. Histologically, such lesions involved the cells of the parvicellular part of the lateral reticular nucleus.4. Placing an electrode, with a diameter of 1 mm, under light pressure on the glycine-sensitive area produced a short-lasting steep rise in blood pressure. The same effect was produced when a current was passed through the electrode to destroy the underlying tissue, but after its destruction the passage of current no longer produced the pressor effect.5. Once the glycine-sensitive area of one side was destroyed, glycine applied to the destroyed area through one of the Perspex rings no longer produced its small depressor effect, but when applied to the intact area of the other side, a pronounced fall in blood pressure occurred. Thus unilateral destruction had the same effect as unilateral glycine application. It potentiated the depressor effect of glycine applied to the other side.6. Following unilateral destruction of the glycine-sensitive area there was only a small fall in blood pressure; following its bilateral destruction blood pressure fell to a low level.7. It is concluded that the cells in the small circumscribed glycine-sensitive areas on the ventral surface of the medulla may play a key role in the maintenance of arterial blood pressure and that the cells of one side are sufficient for this function.

Animals↗

Potentiation of NMDA receptor-mediated responses by dynorphin at low extracellular glycine concentrations.

The effect of dynorphin A(1-13) on N-methyl-D-aspartate (NMDA)-activated currents was investigated in the presence of low extracellular glycine concentrations in Xenopus oocytes expressing recombinant heteromeric NMDA receptors and in cultured hippocampal neurons with the use of voltage-clamp techniques. At an extracellular added glycine concentration of 100 nM, dynorphin A(1-13) (10 microM) greatly increased the amplitude of NMDA-activated currents for all heteromeric subunit combinations tested; on average, the potentiation was: epsilon1/zeta1, 3,377 +/- 1,416% (mean +/- SE); epsilon2/zeta1, 1,897 +/- 893%; epsilon3/zeta1, 4,356 +/- 846%; and epsilon4/zeta1, 1,783 +/- 503%. Potentiation of NMDA-activated current by dynorphin A(1-13) was concentration dependent between 0.1 and 10 microM dynorphin A(1-13), with a half-maximal concentration value of 2.77 microM and an apparent Hill coefficient of 2.53, for epsilon2/zeta1 subunits at 100 nM added extracellular glycine. Percentage potentiation by dynorphin A(1-13) was maximal at the lowest glycine concentrations tested (0.01 and 0.1 microM), and decreased with increasing glycine concentration. No significant potentiation was observed at glycine concentrations > 0.1 microM for epsilon1/zeta1, epsilon2/zeta1, and epsilon4/zeta1 subunits, or at > 1 microM for epsilon3/zeta1 subunits. Potentiation of NMDA-activated currents by dynorphin A(1-13) was not inhibited by 1 microM of the kappa-opioid receptor antagonist nor-binaltorphimine, and potentiation was not observed with 10 microM of the kappa-opioid receptor agonist trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl] benzene-acetamide. Potentiation of NMDA-activated current by dynorphin A(1-13) was inhibited by the glycine antagonist kynurenic acid (50 microM). NMDA-activated current was also potentiated at low glycine concentrations by 10 microM dynorphin A(2-13) or (3-13), both of which have a glycine as the first amino acid, but not by 10 microM dynorphin A(4-13), which does not have glycine as an amino acid. In hippocampal neurons, 10 microM dynorphin A(1-13) or (2-13) potentiated steady-state NMDA-activated current in the absence of added extracellular glycine. The extracellular free glycine concentration, determined by high-performance liquid chromatography, was between 26 and 36 nM for the bathing solution in presence or absence of 10 microM dynorphin A(1-13), (2-13), (3-13), or (4-13), and did not differ significantly among these solutions. The observations are consistent with the potentiation of NMDA-activated current at low extracellular glycine concentrations resulting from an interaction of the glycine amino acids in dynorphin A(1-13) with the glycine coagonist site on the NMDA receptor. Because dynorphin A is an endogenous peptide that can be coreleased with glutamate at glutamatergic synapses, the potentiation of NMDA receptor-mediated responses could be an important physiological regulator of NMDA receptor function at these synapses.

Analgesics, Opioid↗